Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alice T Shaw

Showing results (191-200 of 205) with videos related to

Pageof 21
Sort By:
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Science Translational Medicine|April 5, 2013
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cellsEmre Ozkumur, Ajay M Shah, Jordan C Ciciliano, et al.
Cancer Discovery|February 28, 2018
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsBenjamin J Drapkin, Julie George, Camilla L Christensen, et al.
The New England Journal of Medicine|October 29, 2010
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak, Yung-Jue Bang, D Ross Camidge, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Pageof 21

Showing results (191-200 of 205) with videos related to

Sort By:
Pageof 21
Cancer Discovery|July 20, 2016
Molecular Mechanisms of Resistance to First- and Second-Generation ALK Inhibitors in ALK-Rearranged Lung CancerJustin F Gainor, Leila Dardaei, Satoshi Yoda, et al.
Cancer Cell|July 7, 2015
PF-06463922, an ALK/ROS1 Inhibitor, Overcomes Resistance to First and Second Generation ALK Inhibitors in Preclinical ModelsHelen Y Zou, Luc Friboulet, David P Kodack, et al.
Nature Medicine|March 6, 2018
SHP2 inhibition restores sensitivity in ALK-rearranged non-small-cell lung cancer resistant to ALK inhibitorsLeila Dardaei, Hui Qin Wang, Manrose Singh, et al.
Science Translational Medicine|April 5, 2013
Inertial focusing for tumor antigen-dependent and -independent sorting of rare circulating tumor cellsEmre Ozkumur, Ajay M Shah, Jordan C Ciciliano, et al.
Cancer Discovery|February 28, 2018
Genomic and Functional Fidelity of Small Cell Lung Cancer Patient-Derived XenograftsBenjamin J Drapkin, Julie George, Camilla L Christensen, et al.
The New England Journal of Medicine|October 29, 2010
Anaplastic lymphoma kinase inhibition in non-small-cell lung cancerEunice L Kwak, Yung-Jue Bang, D Ross Camidge, et al.
Cancer Discovery|February 11, 2017
Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)Alexander Drilon, Salvatore Siena, Sai-Hong Ignatius Ou, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in ROS1 fusion-positive non-small-cell lung cancer: integrated analysis of three phase 1-2 trialsAlexander Drilon, Salvatore Siena, Rafal Dziadziuszko, et al.
The Lancet. Oncology|December 16, 2019
Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trialsRobert C Doebele, Alexander Drilon, Luis Paz-Ares, et al.
Nature|July 5, 2023
Therapy-induced APOBEC3A drives evolution of persistent cancer cellsHideko Isozaki, Ramin Sakhtemani, Ammal Abbasi, et al.
Pageof 21